



**Subject:** Progesterone To Prevent Pre-Term Delivery\*

**Effective Date:** October 23, 2007

**Department(s):** Utilization Management

---

**Policy:** Injections of 17 alpha-hydroxyprogesterone caproate (17P) to prevent pre-term labor are reimbursable under Plans administered by QualCare, Inc.

**Objective:** To assure proper and consistent reimbursement and to delineate criteria of coverage of a specific treatment.

**Procedure:**

1. For 17P to be authorized, the patient must have *a* documented current singleton pregnancy **and** a prior history of a singleton pre-term delivery before 37 weeks' gestation *or* prior history of cervical cerclage.
2. When 17P is authorized, weekly intramuscular injections of 17P are covered beginning at 16 weeks of gestation through delivery or the end of the 36<sup>th</sup> week, whichever comes first.
3. Unless the patient is homebound, 17P is reimbursable only in the setting of a doctor's office or outpatient facility.

## References

Dodd JM, Grivell RM, OBrien CM, Dowswell T, Deussen AR. Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy. *Cochrane Database Syst Rev.* 2017;10:CD012024. Epub 2017 Oct 31

Romero R, Conde-Agudelo A, El-Refaie W, Rode L, Brizot ML, et al. Vaginal progesterone decreases preterm birth and neonatal morbidity and mortality in women with a twin gestation and a short cervix: an updated meta-analysis of individual patient data. *Ultrasound Obstet Gynecol.* 2017;49(3):303-314(Mar)

Combs CA, Schuit E, Caritis SN, Lim AC, et al. 17-Hydroxyprogesterone caproate in triplet pregnancy: an individual patient data meta-analysis. *BJOG.* 2016;123(5):682.

Stetson B, Hibbard JU, Wilkins I, Leftwich H. Outcomes With Cerclage Alone Compared With Cerclage Plus 17 $\alpha$ -Hydroxyprogesterone Caproate. *Obstet Gynecol.* 2016;128(5):983-988(Nov-90 ( Apr)

Awwad JI, Usta I, Ghazeeri G, Yacoub N, Succar J, Hayek S, Saasouh W, Nassar A. A randomised controlled double-blind clinical trial of 17-hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity. *BJOG.* 2015;122(1):71-79(Jan)

Romero R, Yeo L, Chaemsaitong P, Chaiworapongsa T, Hassan SS. Progesterone to prevent spontaneous preterm birth. *Semin Fetal Neonatal Med.* 2014;19(1):15-26(Feb)

Iams JD Clinical Practice. Prevention of preterm parturition. *N Engl J Med* 2014;370(3):254-61(Jan)

Defranco EA, Valent AM, Newman T, Regan J, Smith J, Muglia LJ. Adjunctive therapies to cerclage for the prevention of preterm birth: a systematic review. *Obstet Gynecol Int.* 2013;2013:528158. doi: 10.1155/2013/528158. Epub 2013 Mar 27.

Society for Maternal-Fetal Medicine Publications Committee, with the assistance of Vincenzo Berghella, MD. Progesterone and preterm birth prevention: Translating clinical trials data into clinical practice. *Am J Obstet Gynecol.* 2012;206(5):376-386.

Briery CM, Veillon EW, Klauser K, et al. Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. 2011; *Am J Obstet Gynecol.* 204(1): 54.e1-5.

Combs CA, Garite T, Maurel K, et al. Failure of 17-hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double blind, randomized clinical trial.2010; *Am J Obstet Gynecol.* 203(3): 248.e1-9.

Dodd JM, Crowther CA. The role of progesterone in prevention of preterm birth. 2010; *Int J Womens Health.*1:73-84(Aug)

Morse SB, Zheng H, Tany Y, *et al.* Early school-age outcomes of late preterm infants. *Pediatrics* 2009;123(4):e622-e629 (Apr)

Norwitz ER. Prevention of spontaneous preterm birth. *UpToDate* 17.1 Jan 30, 2009. Available at [www.uptodate.com/online/content/topic.do?topicKey=pregcomp/22936&view=print](http://www.uptodate.com/online/content/topic.do?topicKey=pregcomp/22936&view=print). Accessed 04/02/09

Tita ATN, Rouse DJ. Progesterone for preterm birth prevention: an evolving intervention. *Am J Obstet Gynecol* 2009;200(3):219-224 (Mar)

Farine D, Mundle WR, Dodd J, *et al.* The use of progesterone for prevention of preterm birth. *J Obstet gynaecol Can* 2008;30(1):67-77 (Jan)

How HY, Barton JR, Istwan NB, *et al.* Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: Does gestational age at initiation of treatment matter? *Am J Obstet Gynecol* 2007;197(3):260.e1-4 (Sep)

Rouse DJ, Caritis SN, Peaceman AM, *et al.* A Trial of 17 Alpha-Hydroxyprogesterone Caproate to Prevent Prematurity in Twins. *New Eng J Med* 2007;357(5):454-461 (Aug 2)

Fonseca EB, Celik E, Parra M, *et al.* Progesterone and the Risk of Preterm Birth among Women with a Short Cervix. *New Eng J Med* 2007;357(5):462-469 (Aug 2)

Thornton JG. Progesterone and Preterm Labor – Still No Definite Answers. *New Eng J Med* 2007;357(5):499-501 (Aug 2)

Hayes, Inc. Hayes Medical Technology Directory. *Progesterone for the Prevention of Preterm Birth*. Lansdale, PA: Hayes, Inc. July 2, 2007

Rebarber A, Ferra LA, Hanley ML, *et al.* Increased recurrence of preterm delivery with early cessation of 17-alpha –hydroxyprogesterone caproate. *Am J Obstet Gynecol* 2007;196(3):224.e1-224.e4 (Mar)

Mackenzie R, Walker M, Armson A, *et al.* Progesterone for the prevention of preterm birth among women at increased risk: a systematic review and meta-analysis of randomized controlled trials. *Am J Obstet Gynecol* 2006;194(5):1234-1242 (May)

Norwitz ER, Bahtiyar MO, Sibai BM. Defining standards of care in maternal-fetal medicine. *Am J Obstet Gynecol* 2004;191(4):1491-1496 (Oct)

Iams JD. Prevention and Treatment of Preterm Birth. In Ch 23, Preterm Birth, in Gabbe SG, Niebyl JR, Simpson JL. *Obstetrics: Normal and Problem Pregnancies*, 4<sup>th</sup> ed. Philadelphia. Churchill Livingstone. 2002

Drafted By/Date: B. Fisher, MD 09/06/07  
Approved By/Date: QM Committee 10/23/07  
Reviewed without Revision By/Date: B. Fisher, MD 04/02/09  
Approved By/Date: QM Committee 04/28/09  
Revised By/Date: M. McNeil, MD 06/20/11  
Approved By/Date: QM Committee 07/26/11  
Reviewed without Revision By/Date: M. McNeil, MD 07/02/13  
Approved By/Date: QM Committee 07/23/13  
Revised By/Date: M. McNeil, MD 03/22/16  
Approved By/Date: QM Committee 04/19/16  
Review w/o Revision By/Date: M. McNeil, MD 03/05/18  
Approved By/Date: QM Committee 04/17/18

\*Consistent with Summary Plan Description (SPD). When there is discordance between this policy and the SPD, the provisions of the SPD prevail.